Soleno Therapeutics faces class action over alleged safety cover-ups and inflated drug launch claims.

Soleno Therapeutics is the subject of a securities class action alleging it concealed safety risks and inflated commercial success of its drug VYKAT™ XR for Prader-Willi syndrome. The lawsuit claims the company downplayed serious side effects and relied on questionable clinical trial data. After activist reports and disappointing financial results, Soleno's stock dropped sharply. Investors who bought shares between March and November 2025 and suffered losses have until May 5, 2026, to join the case or seek lead plaintiff status.